Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
In the SELECT CV outcome trial, which included patients aged 45 years or older with a body mass index (BMI) 27.0 kg m 2 and established ASCVD but without diabetes, those treated with the glucagon-like peptide-1 receptor agonist (GLP-1RA), semaglutide 2.4 mg, had a 20% MACE reduction compared with those receiving placebo on top of standard of care 12
This does not diminish the therapeutic value of GLP-1 medications but instead underscores the importance of viewing weight loss through a broader physiological lens that accounts for body composition and long-term cardiometabolic health
According to one clinical study, patients taking semaglutide lost an average of 14.9% of their body weight
This is a fundamental principle of patient autonomy
Bydureon BCise is an injectable medication taken under the skin
